Articles tagged "Kidney transplantation"

2017 American Transplant Congress
A Novel KPD Mechanism to Increase Transplants When Some Candidates Have Multiple Willing Donors.
T. Sandholm,¹ G. Farina,¹ J. Dickerson,² R. Leishman,³ D. Stewart,³ R. Formica,⁴ C. Thiessen,⁴ S. Kulkarni.⁴
¹Carnegie Mellon U, Pittsburgh; ²U of Maryland, College Park; ³UNOS, Richmond; ⁴Yale U, New Haven
Purpose: Current kidney exchanges such as the OPTN Kidney Paired Donation (KPD) program allow candidates to list multiple willing donors, but only one will donate…
2017 American Transplant Congress
Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER] Trial.
D. Goldberg, E. Blumberg, R. Reddy, S. Nazarian, V. Van Deerlin, J. Trofe-Clarke, M. Levine, D. Sawinski, R. Bloom, P. Abt, P. Reese.
University of Pennsylvania, Philadelphia
Background: More than 500 kidneys from HCV+ deceased donors are discarded each year, even though direct acting antiviral therapies have cure rates exceeding 95%. We…
2017 American Transplant Congress
Blood Transfusion Induced Donor Specific Antibodies Are Associated with Rejection and Graft Failure.
S. Hassan,¹ F. Regan,^2,3 C. Brown,⁴ A. Harmer,³ N. Anderson,³ P. Brookes,⁵ D. Taube,¹ M. Willicombe.¹
¹Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, United Kingdom; ²Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom; ³NHS Blood and Transplant, London, United Kingdom; ⁴Histocompatibility and Immunogenetics, NHS Blood and Transplant, London, United Kingdom; ⁵Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, United Kingdom
Introduction: Although it is well known that blood transfusions post-transplant are associated with the development of both HLA and donor specific antibodies [DSAs] and a…
2017 American Transplant Congress
Impact of Antihypertensive (AHT) Choice and Advagraf^® Dose on Immunologic Events in Renal Allografts 24 Months Post-Transplantation (Tx).
D. Rush,¹ S. Cockfield,² S. Wilson,³ J. Howell,⁴ FKC-014 Study Group.
¹Health Sciences Centre, Winnipeg, MB, Canada; ²University of Alberta Hospital, Edmonton, AB, Canada; ³Astellas Pharma Global Development, Northbrook, IL; ⁴Astellas Pharma Global Development, Markham, ON, Canada
Renal allograft inflammation may be modulated by ACEi- or ARB-type AHTs (renin-angiotensin system (RAS)-targeting drugs that may inhibit calcineurin) or by optimizing tacrolimus (TAC) exposure.…
2017 American Transplant Congress
Geographic Disparity in Kidney Transplantation After KAS.
S. Zhou,¹ A. Massie,¹ X. Luo,¹ E. Chow,¹ S. Bae,¹ S. Gentry,² S. Gustafson,³ A. Wey,³ B. Thompson,³ N. Salkowski,³ J. Snyder,³ D. Segev.¹
¹JHU, Baltimore; ²USNA, Annapolis; ³CDRG, Minneapolis
The Kidney Allocation System (KAS), implemented in 12/2014, increased regional and national sharing of kidneys. Ideally, broader sharing would also reduce some of the stark…
2017 American Transplant Congress
Tracking the In Vitro Phenotype and Proliferative Capacity of CD57+ CD4 T Cells.
J. Espinosa,¹ J. Lockley,¹ F. Shaw,¹ R. Osborne,¹ M. Joshi,¹ T. Woody,¹ M. Ellis,¹ B. Hollister,¹ J. Cheeseman,¹ R. Townsend,² A. Kirk.¹
¹Duke University, Durham; ²Bristol-Meyers Squibb, Princeton
CD57+PD1- CD4 T cells are primed effectors with increased expression of adhesion molecules capable of infiltrating allografts and mediating belatacept-resistant rejection (BRR). Whether CD57 is…
2017 American Transplant Congress
Factors Predicting 30-Day Hospital Readmission After Kidney Transplant.
J. Ostrem, M. Brokhof, N. Kenyon, E. Hollinger, S. Jensik, O. Olaitan, M. Hertl, N. Alvey.
Rush University Medical Center, Chicago, IL
Background: Hospital readmissions after kidney transplant have been associated with increased morbidity, mortality, decreased quality of life, and increased healthcare costs. The objective of this…
2017 American Transplant Congress
Saftey & Long Term Outcomes of Tocilizumab (Anti-IL6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly-HLA Sensitized (HS) Patients (PTs).
J. Choi,¹ O. Aubert,² A. Vo,¹ A. Loupy,² M. Haas,³ S. Louie,¹ A. Kang,¹ A. Peng,¹ R. Najjar,¹ E. Huang,¹ M. Toyota,⁵ X. Zhang,⁴ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Transplant Group, University Paris Descartes, Paris, France; ³Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA; ⁴Department of HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ⁵Transplant Immunology Lab, Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: DSAs in HS pts lead to poor allograft survival & return to a dialysis. Treatment options for CABMR and TG are limited. IL-6 appears…
2017 American Transplant Congress
Provision of Highly Specialized Aftercare by the Transplant Center Strongly Improves Patient and Allograft Survival in Long-Term Follow-Up After Kidney Transplantation.
T. Schachtner,^1,2,3 P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany; ³Berlin Institute of Health BIH, Berlin, Germany
Despite rapid medical advancements in the field of transplantation, mean kidney allograft survival remained at a standstill. If and to what extent a highly specialized…
2017 American Transplant Congress
Patient and Kidney Allograft Survival in Recipients with End Stage Renal Disease from Amyloidosis.
M. Lim,¹ D. Sawinski,¹ J. Cohen,^1,2 B. Weiss,^3,4 J. Hogan,^1,3 L. Dember.^1,3
¹Renal, Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ³Penn Amyloidosis Program, Division of Hematology-Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; ⁴Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
Background: Data on patient and graft outcomes of kidney transplant recipients with end stage renal disease (ESRD) from systemic amyloidosis is scarce. Methods: We performed…